补体在抗体介导的移植排斥反应中的作用。
The role of complement in antibody mediated transplant rejection.
机构信息
Department of Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
Department of Medicine, University of Wisconsin Madison, Madison, WI, USA.
出版信息
Mol Immunol. 2019 Aug;112:240-246. doi: 10.1016/j.molimm.2019.06.002. Epub 2019 Jun 10.
Abstract
Antibody mediated transplant rejection (AMR) is a major cause of long-term allograft failure, and currently available treatments are of limited efficacy for treating the disease. AMR is caused by donor specific antibodies (DSA) that bind to antigens within the transplanted organ. DSA usually activate the classical pathway of complement within the allograft, and complement activation is believed to be an important cause of tissue injury in AMR. Several new clinical assays may improve our ability to identify patients at risk of AMR. Complement inhibitory drugs have also been tested in selected patients and in small series. Better understanding of the role of complement activation in the pathogenesis of AMR will likely improve our ability to diagnose the disease and to develop novel treatments.
摘要
抗体介导的移植排斥反应 (AMR) 是导致长期移植物失功的主要原因，而目前可用的治疗方法对治疗该疾病的疗效有限。AMR 是由与移植器官内抗原结合的供体特异性抗体 (DSA) 引起的。DSA 通常会激活移植物内补体的经典途径，并且补体激活被认为是 AMR 中组织损伤的重要原因。一些新的临床检测方法可能会提高我们识别 AMR 风险患者的能力。补体抑制药物也已在选定的患者和小系列中进行了测试。更好地了解补体激活在 AMR 发病机制中的作用，可能会提高我们诊断疾病和开发新疗法的能力。
相似文献
1
The role of complement in antibody mediated transplant rejection.
Mol Immunol. 2019 Aug;112:240-246. doi: 10.1016/j.molimm.2019.06.002. Epub 2019 Jun 10.
2
Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.
Transplantation. 2018 Oct;102(10):e431-e438. doi: 10.1097/TP.0000000000002333.
3
Donor-specific HLA antibody-mediated complement activation is a significant indicator of antibody-mediated rejection and poor long-term graft outcome during lung transplantation: a single center cohort study.
Transpl Int. 2018 Jul;31(7):761-772. doi: 10.1111/tri.13149. Epub 2018 Apr 22.
4
The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection.
Trends Mol Med. 2015 May;21(5):319-29. doi: 10.1016/j.molmed.2015.02.004. Epub 2015 Mar 20.
5
Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: A systematic review and meta-analysis.
PLoS Med. 2018 May 25;15(5):e1002572. doi: 10.1371/journal.pmed.1002572. eCollection 2018 May.
6
C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
Transplantation. 2015 Jun;99(6):1151-5. doi: 10.1097/TP.0000000000000699.
7
Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.
Transpl Immunol. 2013 Jun;28(4):148-53. doi: 10.1016/j.trim.2013.05.001. Epub 2013 May 9.
8
9
Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
Transplantation. 2013 Jan 27;95(2):341-6. doi: 10.1097/TP.0b013e3182743cfa.
10
Determining donor-specific antibody C1q-binding ability improves the prediction of antibody-mediated rejection in human leucocyte antigen-incompatible kidney transplantation.
Transpl Int. 2017 Apr;30(4):347-359. doi: 10.1111/tri.12873. Epub 2016 Nov 2.
引用本文的文献
1
Pharmacokinetics, Pharmacodynamics, and Safety of Nipocalimab in Healthy Chinese Volunteers: A Single-Dose, Phase I Study.
Neurol Ther. 2025 May 19. doi: 10.1007/s40120-025-00763-5.
2
Complement in Antibody-Mediated Rejection of the Kidney Graft: From Pathophysiology to Clinical Practice.
J Clin Med. 2025 Apr 18;14(8):2810. doi: 10.3390/jcm14082810.
3
Understanding immunological insights of liver transplantation: a practice for attaining operational tolerance.
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxae125.
4
Functional and phenotypic profiles of HLA-specific antibodies in relation to antibody-mediated kidney transplant rejection.
Hum Immunol. 2025 Mar;86(2):111247. doi: 10.1016/j.humimm.2025.111247. Epub 2025 Jan 30.
5
Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Neonatal Fc Receptor Blocker, in Healthy Japanese Volunteers.
Clin Drug Investig. 2024 Aug;44(8):587-599. doi: 10.1007/s40261-024-01380-0. Epub 2024 Jul 29.
6
Targeted complement inhibition using bispecific antibodies that bind local antigens and endogenous complement regulators.
Front Immunol. 2024 May 16;15:1288597. doi: 10.3389/fimmu.2024.1288597. eCollection 2024.
7
The transplant rejection response involves neutrophil and macrophage adhesion-mediated trogocytosis and is regulated by NFATc3.
Cell Death Dis. 2024 Jan 19;15(1):75. doi: 10.1038/s41419-024-06457-4.
8
Complement Binding Anti-HLA Antibodies and the Survival of Kidney Transplantation.
J Clin Med. 2023 Mar 17;12(6):2335. doi: 10.3390/jcm12062335.
9
Afucosylation of HLA-specific IgG1 as a potential predictor of antibody pathogenicity in kidney transplantation.
Cell Rep Med. 2022 Nov 15;3(11):100818. doi: 10.1016/j.xcrm.2022.100818.
10
Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney.
Front Immunol. 2022 Apr 13;13:845301. doi: 10.3389/fimmu.2022.845301. eCollection 2022.
本文引用的文献
1
Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure.
Kidney Int Rep. 2019 Apr 18;4(8):1057-1065. doi: 10.1016/j.ekir.2019.04.011. eCollection 2019 Aug.
2
How Do We Interpret the Presence of Donor-Specific Antibodies When There Is No Rejection?
Kidney Int Rep. 2019 May 18;4(8):1040-1042. doi: 10.1016/j.ekir.2019.05.008. eCollection 2019 Aug.
3
Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.
Am J Transplant. 2019 Oct;19(10):2865-2875. doi: 10.1111/ajt.15397. Epub 2019 May 24.
4
Glomerular C3 Deposition Is an Independent Risk Factor for Allograft Failure in Kidney Transplant Recipients With Transplant Glomerulopathy.
Kidney Int Rep. 2019 Feb 4;4(4):582-593. doi: 10.1016/j.ekir.2019.01.018. eCollection 2019 Apr.
5
Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial.
Am J Transplant. 2019 Oct;19(10):2876-2888. doi: 10.1111/ajt.15364. Epub 2019 Apr 19.
6
Antibody-Mediated Rejection of Solid-Organ Allografts.
N Engl J Med. 2018 Sep 20;379(12):1150-1160. doi: 10.1056/NEJMra1802677.
7
C5aR1 regulates migration of suppressive myeloid cells required for costimulatory blockade-induced murine allograft survival.
Am J Transplant. 2019 Mar;19(3):633-645. doi: 10.1111/ajt.15072. Epub 2018 Sep 17.
8
ABO-Incompatible Kidney Transplant Outcomes: A Meta-Analysis.
Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1234-1243. doi: 10.2215/CJN.00540118. Epub 2018 Jul 16.
9
A New Classification System for IgG4 Autoantibodies.
Front Immunol. 2018 Feb 12;9:97. doi: 10.3389/fimmu.2018.00097. eCollection 2018.
10
Complement factor H protects mice from ischemic acute kidney injury but is not critical for controlling complement activation by glomerular IgM.
Eur J Immunol. 2018 May;48(5):791-802. doi: 10.1002/eji.201747240. Epub 2018 Feb 22.
Zotero 插件